|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2011-01-01 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
100 项与 MGAM x PRKAB1 相关的临床结果
100 项与 MGAM x PRKAB1 相关的转化医学
0 项与 MGAM x PRKAB1 相关的专利(医药)